Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This randomized clinical trial is conducted to evaluate the effect of three intravitreal
injections of bevasizumab versus two intravitreal injections of triamcinolone in acute
central retinal vein occlusion. The outcomes are visual acuity and central macular thickness.
The follow-up time is 6 months.